Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity Regains Rights To Its Lead Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.

You may also be interested in...



Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer

Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.

Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer

Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.

Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer

Infinity Pharmaceuticals' decision to pull the plug on the registrational Phase III trial with heat shock protein 90 inhibitor IPI-504 - the only product not part of the broad-ranging deal with affiliated specialty pharmas Purdue and Mundipharma - put a chill into investors April 15

Related Content

Topics

UsernamePublicRestriction

Register

PS067114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel